In our study, we applied meloxicam as positive control, because it was reported that ligustrazine reduces inflammatory response following permanent focal cerebral ischemia [30] and traumatic spinal cord [31], regulates inflammation mediators of cardiovascular disease [32], and inhibits TNFα, IL-1β, iNOS, NF-κB p65, COX-2, and IL-8 expression [33, 34]. This evidence concerns the gene TNF and cardiovascular disorder.